Drug Profile
Research programme: retinoic acid receptor-related receptor gamma antagonists - Impetis Biosciences
Alternative Names: RO-10; RO-8; RO-9; ROR-gamma antagonists - Advinus Therapeutics; RORγ antagonist - AdvinusLatest Information Update: 17 Jun 2020
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jun 2020 Preclinical trials in Inflammation in India (PO), before June 2020
- 16 Jun 2020 Research programme: retinoic acid receptor-related receptor gamma antagonists - Impetis Biosciences is available for licensing as of 16 Jun 2020. https://impetisbiosciences.com/
- 16 Jun 2020 The retinoic acid receptor-related receptor gamma inhibitor programme has patent protection